#### This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/23/2023 10:58 AM

# **REDUCE** Varun Beverages

# South Africa acquisition – A good value creation opportunity

# Retail > Company Update > December 20, 2023

With Bevco's acquisition, VBL has access to 10 African nations (incl. 5 existing nations) and now controls most of southern Africa. Among the new regions, South Africa gains significance as its NARTD market is ~40% of India's market, albeit growing at a slower pace (3-5% vol. CAGR). The market is mature, but we remain confident of share gains for VBL, given its strong track record in Zimbabwe and Nepal (over 50% share now). Portfolio-led pricing gain is also a big opportunity, given ~50% lower realizations for Bevco vs. CCBA, a Coke bottler. We also see cluster-based cost synergies, which should further boost earnings growth potential. Acquisition funding (Rs13.2bn) shall be a co-investment from a PE fund and remaining through debt raise by VBL. Acquisition multiple at 0.7x CY23E sales is attractive, in-line with the previous acquisitions and provides a 5x-7x value creation opportunity. Post ~70% run-up in the last 12M, we have a REDUCE rating on VBL. However, consistent outperformance vs. peers and value creation in intl. geos provide scope for further re-rating.

Varun Beverages: Financial Snapshot (Consolidated)					
Y/E March (Rs mn)	CY21	CY22	CY23E	CY24E	CY25E
Revenue	88,232	1,31,731	1,61,262	1,96,772	2,35,701
EBITDA	16,546	27,881	36,035	44,842	54,257
Adj. PAT	6,941	14,975	20,497	25,978	33,508
Adj. EPS (Rs)	5.3	11.5	15.8	20.0	25.8
EBITDA margin (%)	18.8	21.2	22.3	22.8	23.0
EBITDA growth (%)	37.7	68.5	29.2	24.4	21.0
Adj. EPS growth (%)	115.3	115.8	36.9	26.7	29.0
RoE (%)	18.3	32.6	34.3	32.6	31.9
RoIC (%)	11.7	20.9	22.9	25.3	29.4
P/E (x)	219.3	101.6	74.3	58.6	45.4
EV/EBITDA (x)	93.9	55.9	43.4	34.4	28.1
P/B (x)	37.3	29.8	22.2	16.8	12.8
FCFF yield (%)	0.2	0.1	0.2	1.7	1.8

Source: Company, Emkay Research

## SA market is mature; brand/product investments and GTM to aid share gains

SA is a large consumption market (USD5.4bn in FY20) but is a relatively mature market with 60-80% urbanization and high per-capita consumption of ~90L/annum (~4x to that of India). The-Coca-Cola-Company (TCCC) and local brands hold majority share in SA, while Bevco has ~10% volume share through a combination of PepsiCo and its own brands. VBL's success in SA, in our view, will require marketing investments (ATL/BTL) and product/packaging innovation to influence consumer habits. Presence at magic price points also remains key to increasing market share from regional players. However, proof points of success in Zimbabwe/Nepal (>50% share now after starting from scratch) and VBL's best-in-class execution strengths give us confidence of share gains in SA as well.

**Africa – A large and long-term growth opportunity:** PepsiCo's low penetration in Africa and a sizable mix of regional brands offer it a long-term growth opportunity in the continent. We estimate PepsiCo's bottlers cater to 40-45% of the African market (value terms) via its presence in 15 countries, while TCCC addresses the entire African population of >1.25bn (>50 countries). Besides TCCC, which has a healthy share in most African markets, the other competition is regional and can likely be beaten by improving the affordability, affinity, and availability of PepsiCo's products, in our view.

**PepsiCo's wider product portfolio offers a key advantage:** Energy drinks contribute a healthy value share of ~14% in SA (vs. <10% in India), which suggests strong demand for the category in Africa. PepsiCo has built a robust energy-drinks portfolio via the acquisition of Rockstar, its partnership with Starbucks/Bang in USA, and through organic investments in Mountain Dew/Sting. We reckon that a broad-based energy-drinks portfolio across price points should help PepsiCo gain traction in this category in SA.

TARGET PRICE (Rs): 1,150

TARGET FRICE (RS). 1	,150
Target Price – 12M	Dec-24
Change in TP (%)	-
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	(1.8)
CMP (19-Dec-23) (Rs)	1,171.7
Stock Data	Ticker
52-week High (Rs)	1,178
52-week Low (Rs)	550
Shares outstanding (mn)	1,299.2
Market-cap (Rs bn)	1,522
Market-cap (USD mn)	18,300
Net-debt, CY23E (Rs mn)	40,168
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	1,956.7
ADTV-3M (USD mn)	23.5
Free float (%)	36.0
Nifty-50	21,453
INR/USD	83.2
Shareholding, Sep-23	
Promoters (%)	63.1
FPIs/MFs (%)	27.6/3.4

Price Performance						
(%)	1M	3M	12M			
Absolute	12.3	28.5	65.7			
Rel. to Nifty	3.3	20.6	42.3			



#### Devanshu Bansal

devanshu.bansal@emkayglobal.com +91 22 6612 1385

Vishal Panjwani vishal.panjwani@emkayglobal.com +91 22 6624 2431


I his report is intended for feam.emkay@whitemarquesolutions.com use and downloaded at 12/23/2023 10:58 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.



# **Story in Charts**

Exhibit 1: South Africa has a leading per-capita carbonate consumption among African markets

Per Capita SSD Consumption in SA (in litres, FY20)



Source: CCBA Capital Markets Day presentation, Emkay Research, \*SSD is sparkling soft drinks

Exhibit 3: Category mix is better with 36% mix from juice/energy drinks in SA; PepsiCo has a strong energy drinks portfolio




SSD Water Juice Energy, South Africa Market (FY20, %)

Source: CCBA Capital Markets Day presentation, Emkay Research

Exhibit 2: Per-capita consumption is even higher at 88L/annum compared with ~25L in India


Per capita consumption in SA (in Litres, FY20)



Source: CCBA Capital Markets Day presentation, Emkay Research, \*SSD is sparkling soft drinks

Exhibit 4: CCBA has 80%/20% value share in CSD/juice segments in SA, through a combination of TCCC brands and local brands

SSD Juice, CCBA value market share in SA (%)



Source: CCBA Capital Markets Day presentation, Emkay Research

Exhibit 5: Given the turnaround in Zimbabwe, Nepal, and Morocco, we remain confident of market-share led growth for VBL in SA; mediumterm prospects are similar to India and offer a 5x-7x value creation opportunity, in our view

Particulars	CY22	CY25	CY33	CY42	CY22-25E	CY25-33E	CY33-43E
SA market volumes (mn cases)	1,186	1,373	1,897	2,357	5%	4%	2%
VBL's volume market share (%)	9.9	12.1	18.2	25.0			
VBL SA volumes (mn cases)	117	158	341	589	11%	10%	6%
Realization (Rs/case)	136	159	241	370	5%	5%	4%
Revenue (Rs mn)	15,900	25,204	82,283	2,18,035	17%	16%	10%
EBITDA (Rs mn)	1,908	3,251	12,589	39,246	19%	18%	12%
Margin (%)	12.0	12.9	15.3	18.0			

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 12/23/2023 10:58 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 6: VBL has a strong track record of turning around international geographies; now controls >50% market share in Zimbabwe/Nepal, after starting from scratch

			In	ternational o	perations	i
Particulars	CY18	CY19	CY20	CY21	CY22	Remarks
				Zimbab	we	
Revenue (Rs mn)	4,687	5,669	7,235	10,534	10,029	VBL has $>50\%$ market share in Zimbabwe and has grown strongly at a 21% CAGR over CY18-22.
Growth (%)	460	21	28	46	-5	Penetration improvement, product pricing, and efficient operations have helped gain market share.
PAT (Rs mn)	804	-179	1,721	2,273	2,054	Zimbabwe's profitability has improved significantly.
Shareholding (%)	85	85	85	85	85	
Nepal						
Revenue (Rs mn)	4,384	4,755	3,913	4,915	6,599	In Nepal, VBL's market share is ~50%.
Growth (%)	9	8	-18	26	34	Nepal has seen consistent trends with an 11% topline CAGR over CY18-22, despite pandemic-led disruptions
PAT (Rs mn)	388	558	296	-268	295	
Shareholding (%)	100	100	100	100	100	
Morocco						
Revenue (Rs mn)	2,504	3,507	3,281	4,440	6,539	VBL has ${\sim}15\%$ market share in Morocco with only one plant vs. seven plants of competition.
Growth (%)	8	40	-6	35	47	VBL has seen a strong turnaround with the introduction of water line post completion of the non-compete agreement.
PAT (Rs mn)	-696	-195	-170	19	96	Morocco operations have turned profitable since CY20.
Shareholding (%)	100	100	100	100	100	Entry into the foods business is a potential upside

Source: Company, Emkay Research

Exhibit 7: Bevko's existing portfolio consists of both licensed as well as own brands



Source: Company

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 12/23/2023 10:58 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Year	Consolidation date	Manufacturing Unit	Franchise Rights	Company	Ent. Value (Rs mn)
CY17	26-09-2017	Bargarh (Orissa)	Orissa	SMV Beverages	832
CY17	27-09-2017	Bhopal (MP)	Madhya Pradesh	SMV Agencies	47
CY18	11-01-2018	NA	Chhattisgarh SMV Beverages		150
CY18	17-01-2018	NA	NA Bihar Lumbini Beverages		450
CY18	18-01-2018	Cuttack (Orissa)	-	SMV Beverages	438
CY18	23-03-2018	Jamshedpur (Jharkhand)	Jharkhand	SMV Agencies	552
CY18	05-04-2018	Jamshedpur (Jharkhand)	-	Steel City Beverages	102
CY19	14-02-2019	NA	Maharashtra	SMV Beverages	154
CY19	14-02-2019	NA	Karnataka	Nectar Beverages	349
CY19	Q4CY19	Dharwad (Karnataka)	-	Nectar Beverages	747
CY19	01-05-2019	NA	7 States and 5 UTs	PepsiCo India	16,150
CY19	Q4CY19	Tirunelveli (Tamil Nadu)	-	Prathishta Business	200
CY19	Q4CY19	Sricity (Tamil Nadu)	-	Co-Packer	100
	Total Capex				20,270

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 12/23/2023 10:58 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Varun Beverages: Consolidated Financials and Valuations

Profit and Loss					
Y/E December (Rs mn)	CY21	CY22	CY23E	CY24E	CY25E
Revenue	88,232	1,31,731	1,61,262	1,96,772	2,35,701
Revenue growth (%)	36.8	49.3	22.4	22.0	19.8
EBITDA	16,546	27,881	36,035	44,842	54,257
EBITDA growth (%)	37.7	68.5	29.2	24.4	21.0
Depreciation & Amortization	5,313	6,172	6,884	8,184	8,947
EBIT	11,234	21,710	29,152	36,658	45,310
EBIT growth (%)	66.9	93.3	34.3	25.7	23.6
Other operating income	0	0	0	0	0
Other income	679	388	802	450	500
Financial expense	1,847	1,861	2,594	2,209	896
РВТ	10,066	20,237	27,360	34,899	44,914
Extraordinary items	0	0	0	0	0
Taxes	2,606	4,735	6,389	8,376	10,779
Minority interest	(520)	(527)	(474)	(545)	(627)
Income from JV/Associates	0	0	0	0	0
Reported PAT	6,941	14,975	20,497	25,978	33,508
PAT growth (%)	115.3	115.8	36.9	26.7	29.0
Adjusted PAT	6,941	14,975	20,497	25,978	33,508
Diluted EPS (Rs)	5.3	11.5	15.8	20.0	25.8
Diluted EPS growth (%)	115.3	115.8	36.9	26.7	29.0
DPS (Rs)	0.8	1.2	2.3	3.0	3.9
Dividend payout (%)	15.6	10.8	14.3	15.0	15.0
EBITDA margin (%)	18.8	21.2	22.3	22.8	23.0
EBIT margin (%)	12.7	16.5	18.1	18.6	19.2
Effective tax rate (%)	25.9	23.4	23.4	24.0	24.0
NOPLAT (pre-IndAS)	8,326	16,630	22,345	27,860	34,436
Shares outstanding (mn)	1,299.1	1,299.1	1,299.1	1,299.1	1,299.1

Balance Sheet					
Y/E Dec (Rs mn)	CY21	CY22	CY23E	CY24E	CY25E
Share capital	4,330	6,495	6,495	6,495	6,495
Reserves & Surplus	36,469	44,528	62,103	84,184	1,12,666
Net worth	40,799	51,024	68,598	90,679	1,19,161
Minority interests	1,168	1,131	1,131	1,131	1,131
Deferred tax liability (net)	3,111	3,368	3,874	4,455	5,123
Total debt	35,511	40,649	41,366	27,339	8,406
Total liabilities & equity	80,590	96,173	1,14,969	1,23,605	1,33,821
Net tangible fixed assets	57,280	63,571	81,603	83,379	89,424
Net intangible assets	5,586	5,509	5,593	5,632	5,641
Net ROU assets	0	0	0	0	(
Capital WIP	4,966	6,066	6,066	6,066	6,066
Goodwill	242	242	242	242	242
Investments [JV/Associates]	0	0	0	0	(
Cash & equivalents	3,366	2,853	1,198	4,890	5,911
Current assets (ex-cash)	24,379	37,941	45,756	54,433	63,658
Current Liab. & Prov.	15,229	20,010	25,490	31,039	37,122
NWC (ex-cash)	9,150	17,932	20,266	23,394	26,537
Total assets	80,590	96,173	1,14,969	1,23,605	1,33,821
Net debt	32,145	37,797	40,168	22,449	2,495
Capital employed	80,590	96,173	1,14,969	1,23,605	1,33,821
Invested capital	72,257	87,254	1,07,705	1,12,648	1,21,844
BVPS (Rs)	31.4	39.3	52.8	69.8	91.7
Net Debt/Equity (x)	0.8	0.7	0.6	0.2	0.0
Net Debt/EBITDA (x)	1.9	1.4	1.1	0.5	0.0
Interest coverage (x)	0.2	0.1	0.1	0.1	0.0
RoCE (%)	15.6	25.0	28.4	31.1	35.6

Source: Company, Emkay Research

Cash Flows					
Y/E Dec (Rs mn)	CY21	CY22	CY23E	CY24E	CY25E
PBT	10,066	20,237	27,360	34,899	44,914
Others (non-cash items)	5,313	6,172	6,884	8,184	8,947
Taxes paid	(1,754)	(4,478)	(5,883)	(7,795)	(10,111)
Change in NWC	(3,442)	(8,782)	(2,335)	(3,128)	(3,143)
Operating cash flow	12,031	15,010	28,619	34,370	41,503
Capital expenditure	(8,632)	(13,487)	(25,000)	(10,000)	(15,000)
Acquisition of business	0	0	0	0	0
Interest & dividend income	0	0	0	0	0
Investing cash flow	(8,632)	(13,487)	(25,000)	(10,000)	(15,000)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	1,250	3,529	0	(15,000)	(20,000)
Payment of lease liabilities	0	0	0	0	0
Interest paid	(1,847)	(1,861)	(2,594)	(2,209)	(896)
Dividend paid (incl tax)	(1,083)	(1,624)	(2,923)	(3,897)	(5,026)
Others	(253)	(2,081)	243	428	440
Financing cash flow	(1,933)	(2,037)	(5,274)	(20,678)	(25,483)
Net chg in Cash	1,466	(514)	(1,655)	3,692	1,021
OCF	12,031	15,010	28,619	34,370	41,503
Adj. OCF (w/o NWC chg.)	15,472	23,792	30,954	37,498	44,646
FCFF	3,399	1,523	3,619	24,370	26,503
FCFE	1,552	(338)	1,026	22,161	25,607
OCF/EBITDA (%)	72.7	53.8	79.4	76.6	76.5
FCFE/PAT (%)	22.4	(2.3)	5.0	85.3	76.4
FCFF/NOPLAT (%)	40.8	9.2	16.2	87.5	77.0

Source: Company, Emkay Research

Source: Company, Emkay Research

Valuations and Key R	atios				
Y/E Dec	CY21	CY22	CY23E	CY24E	CY25E
P/E (x)	219.3	101.6	74.3	58.6	45.4
P/CE(x)	117.2	67.9	52.4	42.0	33.8
P/B (x)	37.3	29.8	22.2	16.8	12.8
EV/Sales (x)	17.6	11.8	9.7	7.8	6.5
EV/EBITDA (x)	93.9	55.9	43.4	34.4	28.1
EV/EBIT(x)	130.6	67.9	50.6	39.8	31.7
EV/IC (x)	20.3	16.9	13.7	12.9	11.8
FCFF yield (%)	0.2	0.1	0.2	1.7	1.8
FCFE yield (%)	0.1	0.0	0.1	1.5	1.8
Dividend yield (%)	0.1	0.1	0.2	0.3	0.3
DuPont-RoE split					
Net profit margin (%)	7.9	11.4	12.7	13.2	14.2
Total asset turnover (x)	1.2	1.5	1.5	1.6	1.8
Assets/Equity (x)	2.0	1.9	1.8	1.5	1.2
RoE (%)	18.3	32.6	34.3	32.6	31.9
DuPont-RoIC					
NOPLAT margin (%)	9.4	12.6	13.9	14.2	14.6
IC turnover (x)	1.2	1.7	1.7	1.8	2.0
RoIC (%)	11.7	20.9	22.9	25.3	29.4
Operating metrics					
Core NWC days	4.1	6.2	7.1	6.3	6.4
Total NWC days	37.9	49.7	45.9	43.4	41.1
Fixed asset turnover	1.0	1.3	1.4	1.5	1.6
Opex-to-revenue (%)	35.5	31.3	31.5	31.4	31.2

Source: Company, Emkay Research


This report is intended for team emkay@whitemarquesolutions com use and downloaded at 12/23/2023 10:58 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
30-Nov-23	1,105	1,150	Reduce	Devanshu Bansal
06-Nov-23	946	1,150	Buy	Devanshu Bansal
08-Oct-23	927	1,010	Buy	Devanshu Bansal
03-Aug-23	823	970	Buy	Devanshu Bansal
10-Jul-23	812	925	Buy	Devanshu Bansal
25-May-23	809	925	Buy	Devanshu Bansal
02-May-23	708	850	Buy	Devanshu Bansal
09-Apr-23	697	830	Buy	Devanshu Bansal
06-Feb-23	611	685	Hold	Devanshu Bansal
09-Jan-23	654	685	Hold	Devanshu Bansal
01-Nov-22	554	640	Buy	Devanshu Bansal
25-Oct-22	516	610	Buy	Devanshu Bansal
02-Aug-22	458	530	Buy	Devanshu Bansal
29-Apr-22	361	410	Buy	Devanshu Bansal
08-Apr-22	321	383	Buy	Devanshu Bansal
20-Mar-22	316	383	Buy	Devanshu Bansal
04-Feb-22	317	383	Buy	Devanshu Bansal
29-Oct-21	283	373	Buy	Devanshu Bansal
22-Sep-21	305	373	Buy	Devanshu Bansal
03-Aug-21	263	305	Buy	Devanshu Bansal
03-May-21	223	249	Buy	Devanshu Bansal
17-Feb-21	210	229	Buy	Devanshu Bansal

Source: Company, Emkay Research

## **RECOMMENDATION HISTORY - TREND**



Source: Bloomberg, Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 12/23/2023 10:58 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 12/23/2023 10:58 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of December 20, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of December 20, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the December 20, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- 7 EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

#### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 12/23/2023 10:58 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### **OTHER DISCLAIMERS AND DISCLOSURES:**

# Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.